医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Eucure Biopharma

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学製薬　 TimeLine: a Subsidiary of Biocytogen Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using Eucure Biopharma YH003 Antibody Sequence

2022年11月01日

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: a Subsidiary of Biocytogen Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using Eucure Biopharma YH003 Antibody Sequence

2022年11月01日

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: a Subsidiary of Biocytogen Pharmaceuticals and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy Eucure Biopharma Licenses OX40 Antibody YH002

2022年10月18日

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy

バイオテクノロジーヘルスケアヘルス一般製薬　 TimeLine: a Subsidiary of Biocytogen Pharmaceuticals and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy Eucure Biopharma Licenses OX40 Antibody YH002

2022年10月18日